Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- After Settling on October 2019 Re-Pricing, When Will Govt Reveal New Drug Prices?
December 21, 2018
- Clarify Definition of Ads to Not Hamper Info Delivery to Patients: PhRMA Tells Govt
December 21, 2018
- CEFP Finalizes Govt Reform Timeline Urging FY2019 Debate on “Economic Evaluations” for Reimbursement Decisions
December 21, 2018
- Approvals for Epclusa, Keytruda’s MSI-H Indication and More Could Be Delayed into 2019
December 21, 2018
- Chuikyo Snubs Industry’s Call to Exclude Listed Products from CEA Scope
December 20, 2018
- PhRMA, EFPIA Pitch Enhanced Appraisal Model for Japan HTA Plan; Chuikyo Reps Acknowledge ICER Limitations
December 20, 2018
- Govt to Pare Drug Prices by 2.4% in October 2019 Ad-Hoc Re-Pricing
December 19, 2018
- MHLW Revises Conditions of Approval for Alecensa Based on Findings from Post-Marketing Survey
December 19, 2018
- MHLW Compiles Proposal for PMD Law Amendment, Eyes Diet Submission of Related Bill Next Year
December 18, 2018
- Ministers Agree on Ad-Hoc Drug Re-Pricing in October 2019, 29 Billion Yen Saving in State Coffers
December 18, 2018
- MHLW Committee on Medical Devices Recommends Approval of 2 Cancer Gene Panel Tests
December 17, 2018
- MHLW Panel Approves Plan to Amend Blood Law
December 17, 2018
- Govt to Tap R&D Tax Credit System to Push Research on Pediatric Use, Superbug Fight
December 13, 2018
- Authorized Generics for Iressa, Urief to Join NHI Price List; Nesp Biosame Skips Listing
December 13, 2018
- Chuikyo Adopts Outline of 2019 Drug Price Revision for Sales Tax Hike
December 13, 2018
- MHLW to Offer Free Rubella Shots to Men Aged 39-56
December 12, 2018
- MHLW Takes Public Comments on Distribution Management Plan for Shionogi’s ADHD Treatment Vyvanse
December 12, 2018
- Govt’s Draft Reform Timeline Prods MHLW to Discuss Use of “Economic Evaluations” in Reimbursement Decisions in FY2019
December 11, 2018
- Big Improvement in Single-Product, Single-Price Transaction Rate in April-Sept.; Over 90% with Dispensing Pharmacy Chains
December 11, 2018
- Spinraza under PMDA Risk Review for Hydrocephalus
December 10, 2018
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…